Skip to main content
. 2012 Dec 5;23(5):1250–1259. doi: 10.1007/s00330-012-2705-x

Table 2.

Indications for Gd-DOTA-MRI and unenhanced-MRI examinations, evaluable safety population

MRI study area (n,%) Gd-DOTA-MRIa (n = 70) Unenhanced MRIa (n = 44) Totala (n = 114) P-values (Fisher’s exact test)
Body (abdomen/thorax) 37 (52.9 %) 13 (29.5 %) 50 (43.9 %)
  Kidney 23 (32.9 %) 10 (22.7 %) 33 (28.9 %) P = 0.134
  Pelvis 8 (11.4 %) 1 (2.3 %) 9 (7.9 %)
  Limbs 4 (5.7 %) 0 (0.0 %) 4 (3.5 %)
  Liver 0 (0.0 %) 2 (4.5 %) 2 (1.8 %)
  Pancreas 1 (1.4 %) 0 (0.0 %) 1 (0.9 %)
  Heart 1 (1.4 %) 0 (0.0 %) 1 (0.9 %)
Angiography 20 (28.6 %) 5 (11.4 %) 25 (21.9 %)
  Renal 15 (21.4 %) 4 (9.1 %) 19 (16.7 %) P = 0.781
  Carotid 1 (1.4 %) 1 (2.3 %) 2 (1.8 %)
  Aorto-iliac 2 (2.9 %) 0 (0.0 %) 2 (1.8 %)
  Other 2 (2.9 %) 0 (0.0 %) 2 (1.8 %)
Musculoskeletal system (bones/joints) 2 (2.9 %) 14 (31.8 %) 16 (14.0 %)
Central nervous system 1 (1.4 %) 9 (20.5 %) 10 (8.8 %)
  Brain 1 (1.4 %) 7 (15.9 %) 8 (7.0 %) P = 1.000
  Head/neck 0 (0.0 %) 2 (4.5 %) 2 (1.8 %)
Other indications 10 (14.3 %) 6 (13.6 %) 16 (14.0 %)

aA patient with multiple indications is counted several times